The battery type is wrong
Discontinue use and consult a healthcare provider if you experience persistent or concerning symptoms
Water, Air, & Soil Pollution, 229 (3), 54
Concentration (start) Volume (start) = Concentration (final) Volume (final) Purity & Documentation Data Sheet (277 KB) SDS (252 KB) English - EN (252 KB) Franais - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Espaol - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB) Handling Instructions (2659 KB) References [1]
Peptide mass: 10mg Bacteriostatic water: 2mL Concentration: 10mg 2mL = 5 mg/mL = 5,000 mcg/mL Peptide per unit (100-unit syringe): 5 mg 100 = 0.05 mg/unit = 50 mcg/unit If research protocol calls for 250 mcg per research unit: 250 mcg 50 mcg/unit = 5 units on the syringe Total doses per vial at 250 mcg each: 10,000 mcg 250 mcg = 40 research doses That single 10mg vial, reconstituted with 2mL of bacteriostatic water, provides 40 research doses of 250 mcg each, drawn to the 5-unit mark on a standard insulin syringe
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://www.researchgate.net/profile/Asfandyar-Sheikh/publication/256289222/figure/fig1/AS:614177232142337@1523442671231/Mechanism-of-action-of-GLP-1-25.png)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://www.e-enm.org/upload/thumbnails/enm-2024-1942f1.jpg)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://www.researchgate.net/publication/380879316/figure/fig1/AS:11431281256002733@1719453628605/Mechanism-of-action-of-GLP-1-agonists.png)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12933-021-01412-5/MediaObjects/12933_2021_1412_Fig1_HTML.png)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://s3.amazonaws.com/production.scholastica/public/attachments/9c499677-aa6b-4e1e-9360-4d7e41721fd8/large/figure_1._mechanism_of_synthesis_of_glp-1.png)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://www.biochempeg.com/usr/uploads/3/202209/Biological-actions-of%20-GLP-1.png)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://assets.radcliffecardiology.com/s3fs-public/article/2025-10/Figure1-Cardiovascular-Benefits.png?VersionId=xesoRrj7avfA2jOzMQlte7gvUyyjHu67)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a9/12110338/181e20b49ab2/diseases-13-00127-g001.jpg)
![moa of glp 1 agonists Mechanism action of GLP-1 [25] Current Insights, Advantages and Challenges](https://www.amjmed.com/cms/10.1016/j.amjmed.2025.01.021/asset/3229fc1b-34b3-4be6-8fab-b5e0f64772c1/main.assets/gr1.jpg)
